KYNA acts as an antagonist of N-methyl-d-aspartate and α-7 nicotinic acetylcholine receptors (NMDAR, α7nAChR), both of them involved in the schizophrenia pathogenesis [24,25,26]. The gene discussed is CHRNA7; the disease is schizophrenia.